Tag Archives: Epizyme

Roth Capital Thinks Epizyme’s Stock is Going to Recover

In a report released today, Jotin Marango from Roth Capital reiterated a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $26. The company’s shares closed on Friday at $10.25, close to its 52-week low of $8.61. Marango

Epizyme (EPZM) Received its Third Buy in a Row

After Oppenheimer and Cowen & Co. gave Epizyme (NASDAQ: EPZM) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein reiterated a Buy rating on Epizyme today and set a price target

Oppenheimer Maintains Their Buy Rating on Epizyme (EPZM)

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $27. The company’s shares opened today at $12.60. Cann commented: “Epizyme’s Q2 loss per share of $0.42

Analysts Offer Insights on Healthcare Companies: Epizyme (NASDAQ: EPZM) and Achaogen (NASDAQ: AKAO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Epizyme (NASDAQ: EPZM) and Achaogen (NASDAQ: AKAO) with bullish sentiments. Epizyme (NASDAQ: EPZM) In a report released today, Andrew Fein from H.C.

Analysts Offer Insights on Healthcare Companies: Epizyme (NASDAQ: EPZM), Wright Medical Group (NASDAQ: WMGI) and Illumina (NASDAQ: ILMN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Epizyme (NASDAQ: EPZM), Wright Medical Group (NASDAQ: WMGI) and Illumina (NASDAQ: ILMN) with bullish sentiments. Epizyme (NASDAQ: EPZM) In a report issued

H.C. Wainwright Gives a Buy Rating to Epizyme

H.C. Wainwright analyst Andrew Fein assigned a Buy rating to Epizyme (NASDAQ: EPZM) today and set a price target of $25. The company’s shares closed on Friday at $17. Fein noted: “We believe EPZM’s trial is no exception. As far